Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Plc Regulatory News (HAYD)

Share Price Information for Haydale Plc (HAYD)

Share Price is delayed by 15 minutes
Get Live Data
0.3275    0.00 (0.00%)
Bid:
0.325
Ask:
0.33
Spread: 0.005 (1.538%)
Market Cap: £25.46m
HAYD Live PriceLast checked at - London Stock Exchange

Intraday Haydale Plc Share Chart

Director/PDMR Shareholding

1 Mar 2022 17:26

RNS Number : 2782D
Haydale Graphene Industries PLC
01 March 2022
 

For immediate release

1 March 2022

 

Haydale Graphene Industries plc

 

('Haydale' or the 'Group')

 

Director/PDMR Shareholding

 

Haydale, (AIM: HAYD), the global advanced materials group, has today been informed that Mark Chapman, Chief Financial Officer of the Company has transferred 285,714 ordinary shares of 2p each in the Company ("Ordinary Shares") from his personal holding into his ISA. Following this transaction Mr Chapman's interest in Company remains unchanged.

 

For further information:

 

Haydale Graphene Industries plc

Keith Broadbent, Chief Executive Officer

Mark Chapman, Chief Financial Officer

Tel: +44 (0) 1269 842 946

 

finnCap (Nominated Adviser & Broker)

Julian Blunt/Edward Whiley, Corporate Finance

Andrew Burdis, ECM

Tel: +44 (0) 20 7220 0500 

 

 

 

 

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jonathan Mark Chapman

2

Reason for notification

 

 

a.

Position/Status

Chief Financial Officer of Haydale Graphene Industries plc

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Haydale Graphene Industries Plc

b.

LEI

213800KNULBQFF25IE72

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary Shares of 2p each

 

GB00BKWQ1135

b.

Nature of the transaction

Transfer of Shares to ISA via a sale and purchase.

c.

Price(s) and volume(s)

Price(s)

Volume(s)

 0.0440p Sale

 285,714

 0.0441p Purchase

285,714

d.

Aggregated information

 

- Aggregated Volume

 

- Price

As above

 

e.

Date of the transaction

1 March 2022

f.

Place of the transaction

AIMX - LONDON STOCK EXCHANGE - AIM MTF.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBRGDXUDGDGDB
Date   Source Headline
21st May 20267:05 amRNSProposed Commercial Relationship
8th Apr 20265:18 pmRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSNew Contract Signed
26th Mar 20263:39 pmRNSResult of AGM
6th Mar 20261:31 pmRNSInvestor Presentation via Investor Meet Company
2nd Mar 20267:00 amRNSStrategic Digital Infrastructure Partnership
17th Feb 20267:00 amRNSFinal Results and Post-Period Trading Update
11th Feb 20267:00 amRNSNotice of Annual Results
30th Jan 20269:45 amRNSTotal Voting Rights
22nd Jan 20264:54 pmRNSHolding(s) in Company
22nd Jan 20267:00 amRNSHolding(s) in Company
21st Jan 202612:31 pmRNSHolding(s) in Company
15th Jan 20265:01 pmRNSHolding(s) in Company
15th Jan 20262:44 pmRNSChange of Name
12th Jan 20267:00 amRNSCompletion of Acquisition
9th Jan 20266:19 pmRNSDirector/PDMR Dealings
8th Jan 20261:59 pmRNSHolding(s) in Company
8th Jan 20261:55 pmRNSHolding(s) in Company
6th Jan 20262:45 pmRNSResult of General Meeting and Total Voting Rights
22nd Dec 20252:08 pmRNSHolding(s) in Company
22nd Dec 20252:08 pmRNSHolding(s) in Company
16th Dec 202512:45 pmRNSResult of Retail Offer
15th Dec 20259:14 amRNSResult of Accelerated Bookbuild
12th Dec 20257:05 amRNSRetail Offer
12th Dec 20257:00 amRNSProposed Fundraise and Acquisition
2nd Dec 20257:00 amRNSCommercial Update
30th Oct 202510:45 amRNSExpansion of Commercial Platform
23rd Oct 20257:00 amRNSContract Wins
11th Sep 20257:00 amRNSStrategic Collaboration and Trading Update
8th Aug 20257:00 amRNSGrant of Share Options and PDMR Dealings
11th Jul 20258:21 amRNSHolding(s) in Company
30th Jun 20253:14 pmRNSHolding(s) in Company
26th Jun 20252:00 pmRNSSubscriptions, Director Dealings & Issue of Equity
12th Jun 20252:12 pmRNSTrading Update
23rd Apr 20255:22 pmRNSDirectorate Change
17th Apr 202510:46 amRNSCorrection: Haydale US Sales Process Update
17th Apr 20257:00 amRNSHaydale US Sales Process Update
2nd Apr 20257:00 amRNSHaydale Achieves CE Certification
13th Mar 20252:15 pmRNSSubscription, Director Dealings and TVR
13th Mar 20257:00 amRNSInterim Results
7th Mar 202510:18 amRNSHaydale US sales process update
10th Feb 20257:00 amRNSHaydale US placed into insolvency process
30th Dec 20245:20 pmRNSReplacement: Result of AGM
30th Dec 202412:48 pmRNSResult of AGM
23rd Dec 20247:05 amRNSDisposal of Korean Subsidiary
23rd Dec 20247:00 amRNSBusiness Review and Appointment of CEO
6th Dec 20247:00 amRNSPosting of Annual Report and Notice of AGM
4th Dec 20249:44 amRNSHolding(s) in Company
3rd Dec 20245:38 pmRNSHolding(s) in Company
2nd Dec 20247:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.